Breadcrumb AMCP.org Policy & Advocacy Letters, Statements & Analysis AMCP Submits Comments to the FDA on the Biosimilar Interchangeability Draft Guidance Seeking Additional Clarity Prior to Finalization AMCP Submits Comments to the FDA on the Biosimilar Interchangeability Draft Guidance Seeking Additional Clarity Prior to Finalization 5/19/17 Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page AMCP Comments Re FDA Biosimilars Interchangability Draft Guidance.pdf Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page